FTC ex­pands phar­ma scruti­ny to ear­ly-stage deals, forc­ing Sanofi to drop Pompe dis­ease part­ner­ship with Maze

The Fed­er­al Trade Com­mis­sion said it would seek to block Sanofi’s pro­posed li­cens­ing deal for Maze Ther­a­peu­tics’ clin­i­cal-stage Pompe dis­ease treat­ment, lead­ing the French phar­ma to say it would back out of the agree­ment.

Sanofi al­ready mar­kets Nexvi­azyme, a suc­ces­sor to its own My­ozyme/Lu­mizyme, and the US reg­u­la­tor said Mon­day that the up to $755 mil­lion pro­posed deal “would elim­i­nate a nascent com­peti­tor poised to chal­lenge Sanofi’s mo­nop­oly in the Pompe dis­ease ther­a­py mar­ket.” The agency au­tho­rized a law­suit in fed­er­al court, it said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER